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Introduction {#sec005}
============

Cancers contribute a greatest deal to death worldwide \[[@pone.0135318.ref001]\], as a result of interactions between genetic mutation accumulation and environment risk factors. Genetic variation plays an important role in the tumorigenesis with the effect on gene structure and protein expression \[[@pone.0135318.ref002]\]. Several polymorphisms that have relationship with cancers in the human osteopontin (OPN) encoding gene *SPP1* have been searched.

OPN is a secreted glycophosphoprotein that may physiologically serve as a cytokine and an extracellular matrix molecule. It is expressed and secreted by various cells, and plays a role in bone remodeling, reconfiguration of tissue integrity during inflammatory processes, coronary restenosis, and cancer metastatic \[[@pone.0135318.ref003]--[@pone.0135318.ref006]\]. It has been demonstrated that OPN is associated with more than 30 cancers so far and a marker for breast, cervical, colorectal, head and neck, liver, lung, ovarian and prostate cancers, as well as for sarcoma \[[@pone.0135318.ref007],[@pone.0135318.ref008]\]. The tight correlation with tumor metastatic and progression was initially reported in 1979 \[[@pone.0135318.ref009]\] and had been approved by many studies, however, the association between OPN and carcinogenesis has just been researched recently \[[@pone.0135318.ref010],[@pone.0135318.ref011]\]. The expression of OPN was significantly influenced by its genetic polymorphisms of the promoter \[[@pone.0135318.ref012]\], *SPP1* (mapped to chromosome 4q24-q25), which is predominantly a transcriptionally regulated gene with highly conserved promoter \[[@pone.0135318.ref013]\]. Several polymorphisms in the *SPP1* gene affect OPN expression and the level of its secretion into bovine milk \[[@pone.0135318.ref014]\]. Common single nucleotide polymorphisms (SNPs) such as -443C\>T (rs11730582), -156G\>GG (rs17524488) and -66T\>G (rs28357094) may result in increased expression of *SPP1* gene and tumor risk. The results remain inconclusive and a comprehensive analysis is necessary. Therefore, we implemented a meta-analysis that integrated all studies for *SPP1*polymorphisms and risk for all types of human cancer in order to obtain an accurate assessment.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

A literature research was conducted using PubMed, Web of Science, Embase, and Cochrane Library up to March 2015 without language restrictions. Relevant studies were searched using the terms \[osteopontin or OPN or *SPP1*\] AND \[-443C\>T or rs11730582 or -156G\>GG or rs17524488 or -66T\>G or rs28357094\] AND \[variant or genetic polymorphism or polymorphism or mutation\]. Additional studies were identified by screening references in the retrieved articles and preceding reviews on the topic.

Inclusion criteria and exclusion criteria {#sec008}
-----------------------------------------

Studies were included if they met the following criteria: (1) case--control study; (2) about the associations between *SPP1* polymorphisms (-443T\>C or -156G\>GG or -66T\>G) and cancer risks; and (3) had available genotype frequencies of cases and controls or could be calculated from the paper. Accordingly, the exclusion criteria were (1) duplicate data, (2) only for cancer samples, (3) only for benign disease compared with controls, and (4) number of the cases less than 30.

Data extraction and quality assessment {#sec009}
--------------------------------------

Two of the authors independently selected the article and extracted data with consensus on all of the terms. If the data was not identical, the two investigators would check the data again to come to an agreement. If they could not reach an agreement, an expert (Weiguo Dong) would participate in the discussion. Following items were collected from the eligible articles: first author's name, year of publication, country of origin, ethnicity, cancer type, number of cases and controls, age, gender, OPN levels and genotypes distributions in cases and controls.

The quality of selected studies was independently evaluated on basis of Newcastle-Ottawa scale (NOS) \[[@pone.0135318.ref015]\]. Studies with six or more stars were considered as high quality.

Statistical analysis {#sec010}
--------------------

Meta-analysis was performed using the Cochrane Collaboration Revman 5.3 (Copenhagen, 2014) and STATS package version 9.2 (Stata corporation, College Station, Texas). The risk of cancer associated with three polymorphisms respectively of *SPP1* gene was estimated for each eligible study by odds ratio (OR) and 95% confidence interval (95% CI). We used χ^2^-based Q statistic text \[[@pone.0135318.ref016]\] and *I* ^*2*^ index \[[@pone.0135318.ref017]\] to assess the heterogeneity between the studies. When heterogeneity across studies (Q test P≤0.05 or *I* ^*2*^ \>50%) was showed, random-effect model was used \[[@pone.0135318.ref018]\], otherwise, the fixed-effects model was used \[[@pone.0135318.ref019]\]. Hardy-Weinberg equilibrium (HWE) in control people was judged by χ^2^ text. We evaluated the associations of three polymorphisms with cancer risk under dominant, recessive, codominant, and heterozygote models respectively. Then, we analyzed the sensitivity to evaluate the stability of results after removing the studies deviating from HWE. Publication bias was diagnosed with Begg's funnel plot \[[@pone.0135318.ref020]\] and Egger's linear regression \[[@pone.0135318.ref021]\]. P\<0.05 was regarded as a state of disequilibrium.

Results {#sec011}
=======

Study characteristics {#sec012}
---------------------

The search strategy retrieved 40 potential relevant studies and one study was identified through references. According to the inclusion and exclusion criteria, 11 studies \[[@pone.0135318.ref010],[@pone.0135318.ref012],[@pone.0135318.ref022]--[@pone.0135318.ref030]\]with full text were eligible for this meta-analysis and 30 studies were excluded. The flow chart of study selection is summarized in [Fig 1](#pone.0135318.g001){ref-type="fig"}. All studies taken in China and all participators came from Chinese population. There were eleven case-control studies with 3130 cancer cases and 3828 controls concerning -443T\>C polymorphism, ten case-control studies with 3019 cases and 3615 controls concerning -156 G\>GG, and eight case-control studies with 2258 cases and 2846 controls concerning -66T\>G. Cancer types include glioma, non-small-cell lung cancer (NSCLC), oral squamous cell carcinoma (OSCC), gastric cancer (GC), papillary thyroid cancer (PTC), nasopharyngeal carcinoma (NPC), cervical cancer, acute myeloid leukemia (AML), and intrahepatic cholangiocarcinoma (ICC). Blood samples were used to determine genetic polymorphisms in all of the included studies. The distribution of genotypes in the controls was consistent with HWE for all selected studies except for two studies \[[@pone.0135318.ref023],[@pone.0135318.ref029]\]. The qualities of all included studies were categorized as high quality. [Table 1](#pone.0135318.t001){ref-type="table"} showed the characteristics and NOS quality of the enrolled studies.

![Flow chart showing study selection procedure.](pone.0135318.g001){#pone.0135318.g001}

10.1371/journal.pone.0135318.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0135318.t001){#pone.0135318.t001g}

  Study       Year   Cancer type       Number     Age, mean ± SD, year   Gender (male, %)   Genotype (case/control)   P~HWE~    NOS                         
  ----------- ------ ----------------- ---------- ---------------------- ------------------ ------------------------- --------- --------- -------- -------- ---
  -443T\>C                                                                                                                                                  
   Chen JX    2010   Glioma            670 /680   NR                     NR                 59.7/54.6                 299/284   299/311   69/77    0.557    7
   Chen YZ    2013   NSCLC             360/360    57.2                   56.3               55.3/54.7                 164/153   165/163   31/44    0.954    7
   Chiu YW    2010   OSCC              97/100     53.6                   NR                 88.7/NR                   47/33     41/50     9/17     0.793    8
   Lee TY     2013   GC                146/128    64.0±13.9              61.4±8.5           59.6/57.0                 59/65     66/55     21/8     0.416    7
   Mu GY      2013   PTC               363/413    38.6±2.1               38.4±4.3           39.4/49.4                 73/164    171/187   119/62   0.469    8
   Shen ZP    2014   Glioma            248/281    45.2±3.5               44.9±4.1           46.7/45.7                 54/90     113/137   81/54    0.885    9
   Wang JL    2014   NPC               108/210    48.2±10.5              47.8±11.2          66.7/57.1                 60/85     38/95     10/30    0.678    8
   Xu Q       2011   Cervical cancer   300/774    54.6±5.7               54.5±2.6           0/0                       227/343   49/334    24/106   0.126    7
   Zhang R    2015   AML               381/430    54.5±3.6               54.6±4.1           51.7/52.1                 81/117    183/223   117/90   0.392    7
   Zhao FJ    2012   GC                200/200    56.3±3.5               55.7±4.2           65.0/65.0                 91/85     94/93     15/22    0.646    7
   Zhao XQ    2014   ICC               260/260    57.2±NR                56.3±NR            57.3/56.5                 120/114   111/115   29/31    0.809    8
  -156G\>GG                                                                                                                                                 
   Chen JX    2010   Glioma            670 /680   NR                     NR                 59.7/54.6                 220/273   345/306   99/90    0.772    7
   Chen YZ    2013   NSCLC             360/360    57.2                   56.3               55.3/54.7                 137/155   150/136   73/69    0.0001   7
   Chiu YW    2010   OSCC              97/100     53.6                   NR                 88.7/NR                   27/42     52/49     18/9     0.318    8
   Lee TY     2013   GC                146/128    64.0±13.9              61.4±8.5           59.6/57.0                 48/46     72/64     26/18    0.911    7
   Mu GY      2013   PTC               363/413    38.6±2.1               38.4±4.3           39.4/49.4                 104/100   187/219   72/94    0.217    8
   Shen ZP    2014   Glioma            248/281    45.2±3.5               44.9±4.1           46.7/45.7                 57/67     124/153   67/61    0.134    9
   Xu Q       2011   Cervical cancer   300/774    54.6±5.7               54.5±2.6           0/0                       88/287    129/359   83/128   0.318    7
   Zhang R    2015   AML               381/430    54.5±3.6               54.6±4.1           51.7/52.1                 84/114    198/226   99/90    0.259    7
   Zhao FJ    2012   GC                200/200    56.3±3.5               55.7±4.2           65.0/65.0                 67/86     92/78     41/36    0.017    7
   Zhao XQ    2014   ICC               260/260    57.2±NR                56.3±NR            57.3/56.5                 111/107   101/110   48/43    0.109    8
  -66T\>G                                                                                                                                                   
   Chen YZ    2013   NSCLC             360/360    57.2                   56.3               55.3/54.7                 356/351   4/9       0/0      0.81     7
   Lee TY     2013   GC                146/128    64.0±13.9              61.4±8.5           59.6/57.0                 146/128   0/0       0/0      NA       7
   Mu GY      2013   PTC               363/413    38.6±2.1               38.4±4.3           39.4/49.4                 99/114    167/191   97/108   0.128    8
   Shen ZP    2014   Glioma            248/281    45.2±3.5               44.9±4.1           46.7/45.7                 83/88     130/147   35/46    0.239    9
   Xu Q       2011   Cervical cancer   300/774    54.6±5.7               54.5±2.6           0/0                       97/181    199/210   93/121   0.668    7
   Zhang R    2015   AML               381/430    54.5±3.6               54.6±4.1           51.7/52.1                 89/99     199/210   93/121   0.668    7
   Zhao FJ    2012   GC                200/200    56.3±3.5               55.7±4.2           65.0/65.0                 200/200   0/0       0/0      NA       7
   Zhao XQ    2014   ICC               260/260    57.2±NR                56.3±NR            57.3/56.5                 256/251   4/9       0/0      0.776    8

P~HWE~ was calculated by goodness-of fit χ^2^-test, P~HWE~ \<0.05 was considered statistically significant; Ht, heterozygote; HWE, Hardy--Weinberg equilibrium; NA, not available; VR Ho, variant homozygote; WT Ho, wild-type homozygote.

Quantitative data synthesis {#sec013}
---------------------------

For -443T\>C polymorphism, eleven case-control studies \[[@pone.0135318.ref010],[@pone.0135318.ref012],[@pone.0135318.ref022]--[@pone.0135318.ref030]\] with 3130 cases and 3828 controls were identified. Overall, there is no significant difference in -443T\>C genotype distribution between cancer and control \[dominant model (OR = 0.93, 95%CI 0.62--1.38, *P*\<0.0001); recessive model (OR = 1.06, 95%CI 0.73--1.55, *P*\<0.0001); CT vs TT model (OR = 0.88, 95%CI 0.62--1.26, *P*\<0.0001); CC vs TT model (OR = 1.03, 95%CI 0.61--1.73, *P*\<0.0001)\] ([Table 2](#pone.0135318.t002){ref-type="table"}).

10.1371/journal.pone.0135318.t002

###### Summary of ORs of the *SPP1* polymorphisms and cancer risk.

![](pone.0135318.t002){#pone.0135318.t002g}

  SNP                 n    Dominant model    Recessive model   Ht versus WT Ho                             VR Ho versus WT Ho                                                                                                                                                                                         
  ------------------- ---- ----------------- ----------------- ------------------------------------------- -------------------- ------ ------------------------------------------- ----------------- ------ ------------------------------------------- ----------------- ------------------------------------------- -----
  -443T/C             11   0.93(0.62,1.38)   .000              93%                                         1.06(0.73,1.55)      .000   85%                                         0.88(0.62,1.26)   .000   90%                                         1.03(0.61,1.73)   .000                                        91%
  -156G/GG                                                                                                                                                                                                                                                                                                            
   Total              10   1.22(1.10,1.35)   .09               40%[^b^](#t002fn003){ref-type="table-fn"}   1.25(1.10,1.41)      .07    43%[^b^](#t002fn003){ref-type="table-fn"}   1.18(1.06,1.32)   .15    32%[^b^](#t002fn003){ref-type="table-fn"}   1.35(1.09,1.68)   .03                                         52%
   Studies with HWE   8    1.20(1.07,1.35)   0.05              50%[^b^](#t002fn003){ref-type="table-fn"}   1.29(1.05,1.60)      .07    53%                                         1.13(1.00,1.28)   0.16   33%[^b^](#t002fn003){ref-type="table-fn"}   1.37(1.05,1.80)   0.01                                        62%
  -66T/G              8    0.84(0.71,0.98)   .15               38%[^b^](#t002fn003){ref-type="table-fn"}   1.02(0.79,1.32)      .07    57%                                         0.76(0.54,1.08)   .006   70%                                         0.91(0.74,1.10)   .87[^b^](#t002fn003){ref-type="table-fn"}   0

n: number of studies.

^a^Test for heterogeneity.

^b^Fixed-effect model was used when the P for heterogeneity test was\>0.05 or I^2^≤50%, otherwise the random-effect model was used.

CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism; Ht+VR Ho vs WT Ho, dominant model; VR Ho vs Ht+WT Ho, recessive model.

For -156G\>GG polymorphism, ten case-control studies \[[@pone.0135318.ref012],[@pone.0135318.ref022]--[@pone.0135318.ref030]\] with 3019 cases and 3615 controls were identified. Overall, a significant increased risk was found under all four models \[dominant model (OR = 1.22, 95%CI 1.10--1.35, *P* = 0.09); recessive model (OR = 1.25, 95%CI 1.10--1.41, *P* = 0.07); GGG vs GG model (OR = 1.18, 95%CI 1.06--1.32, *P* = 0.15); GGGG vs GG model (OR = 1.35, 95%CI 1.09--1.68, *P* = 0.03)\] ([Table 2](#pone.0135318.t002){ref-type="table"}). We evaluated the influence of these studies on the pooled OR by deleting the studies that were not in HWE from the meta-analysis. The estimated pooled odd ratio still did not change at all ([Table 2](#pone.0135318.t002){ref-type="table"}).

For -66T\>G polymorphism, eight case-control studies \[[@pone.0135318.ref023]--[@pone.0135318.ref030]\] with 2258 cases and 2846 controls were identified. Overall, we found that a significant decreased risk under dominant model (OR = 0.84, 95%CI 0.71--0.98, *P* = 0.15), but no significant association was found under other three models ([Table 2](#pone.0135318.t002){ref-type="table"}).

Heterogeneity and sensitivity analysis {#sec014}
--------------------------------------

For -443T\>C polymorphism, there was significant heterogeneity for overall comparisons under all four models (*P*\<0.0001). For -156G\>GG polymorphism, significant heterogeneity between studies was observed in overall comparisons under GG/GG versus GG model (*I* ^2^ = 52%, *P* = 0.03). And for -66T\>G polymorphism, significant heterogeneity between studies was found in overall comparisons under recessive model and TG versus TT model (*I* ^*2*^ = 57%, *P* = 0.07; *I* ^*2*^ = 0.006, *P* = 70%, respectively). ([Fig 2](#pone.0135318.g002){ref-type="fig"}). Then, sensitivity analysis was performed to evaluate the stability of the results by removing one study one by one. For -156G\>GG polymorphism, the heterogeneity decreased when exclude the study by Mu GY, so it suggests that Mu GY may be the source of heterogeneity. For -66 T\>G polymorphism, the heterogeneity decreased to zero when the study of Xu Q were excluded, so the particular study may be the source of heterogeneity.

![Meta-analysis of the association between *SPP1* polymorphisms and susceptibility to cancer under dominant model.\
(a) -443 T\>C. (b) -156G\>GG. (c)-156G\>GG with HWE. (d) -66T\>G.](pone.0135318.g002){#pone.0135318.g002}

Publication bias {#sec015}
----------------

Begg's funnel plot and Egger's test were performed to address potential publication bias in the available literature. The shape of funnel plots did not indicate any evidence of funnel plot asymmetry ([Fig 3](#pone.0135318.g003){ref-type="fig"}). Egger's test also reveal that there was no statistical significance for evaluation of publication bias under dominant model (-443T\>C: *P* = 0.818, -156G\>GG: *P* = 0.418, -66T\>G: *P* = 0.842).

![Begg's funnel plot for publication bias under dominant model.\
(a) -443T\>G. (b) -156G\>GG. (c) −66T\>G](pone.0135318.g003){#pone.0135318.g003}

Discussion {#sec016}
==========

Osteopontin is a member of small intrgrin-binding ligand N-linked glycoproteins (SIBLINGs) family. There are many pieces of evidences indicating that osteopontin profoundly regulate the development and progression of various tumors. Additionally, OPN expression was significantly higher in human cancers tissues than in matched normal tissues and it was significantly associated with nodal metastasis and more advanced clinical stage. Therefore, numerous publications have tested OPN as a biomarker for cancer invasiveness \[[@pone.0135318.ref031]--[@pone.0135318.ref034]\]. However, the associations with tumorigenesis have not been proved well. Polymorphisms in the OPN gene, *SPP1*, may potentially alter the expression of OPN and then modulate the risk for cancer. In recent years, SNPs have been identified as a powerful tool for predicting some complex diseases. However, previous genetic epidemiological studies about the associations between OPN gene polymorphisms and the risk of human cancer are limited, and the results were inconclusive. To our knowledge, this is the first meta-analysis which investigated the possible correlations of rs11730582 (-443 T\>C), rs17524488 (-156G\>GG), and rs28357094 (-66T\>G) polymorphisms in the *SPP1* gene with cancer susceptibility.

Our results revealed that -443T\>C polymorphism might have no relation with pathogenesis of cancer. And we found that different studies had inconsistent results about this polymorphism even for the same cancer. For example, Chen JX \[[@pone.0135318.ref022]\] said that in a recessive genetic model TC + CC genotypes significantly decrease the risk of glioma when compared with TT, but Shen ZP \[[@pone.0135318.ref026]\] considered that the glioma patients had markedly high frequency of -443CC genotype than controls. Another two studies \[[@pone.0135318.ref029],[@pone.0135318.ref030]\] showed that there was no significant difference in the distribution of -443 between cancer patients and controls. What's more, large heterogeneity was found in four gene models (P\<0.0001). Previous meta-analysis about human cancer risk found that the cancer type might contribute most to the source of heterogeneity \[[@pone.0135318.ref035],[@pone.0135318.ref036]\]. In this study, the subgroup analysis on basis of cancer types was not calculated because of the limited number of studies. So this result should be interpreted with caution.

For -156G\>GG, our study found that GG allele was at significant high risk for cancer under all four genetic models, and this result was confirmed among studies in HWE. When we exclude the study of Mu GY \[[@pone.0135318.ref025]\] which may be source of the heterogeneity, the results remain unchanged. That means the SNP of -156G\>GG may considerably act a potential candidate of biomarker for cancer risk.

The meta-analysis of -66T\>G include eight studies, however, two studies \[[@pone.0135318.ref024],[@pone.0135318.ref029]\] that was not estimable in meta-analysis ([Fig 2](#pone.0135318.g002){ref-type="fig"}). The results of polymorphism in a dominant model showed that the genotypes TG+ GG significantly decreased the risk of cancer when compared with TT. Noteworthy, the association was disappear when exclude the study of Xu Q \[[@pone.0135318.ref027]\] that may be the source of the heterogeneity. So, the result is instable and further studies are necessary to clarify the association.

High OPN expression in the primary tumors is associated with cancer risk, metastasis and poor clinical outcome \[[@pone.0135318.ref037]--[@pone.0135318.ref039]\]. The previous study showed that -443 promoter region exerts influence on OPN gene expression in melanoma cells \[[@pone.0135318.ref040]\]. In our including studies, four studies \[[@pone.0135318.ref010],[@pone.0135318.ref025],[@pone.0135318.ref026],[@pone.0135318.ref028]\] observed the association of OPN levels and *SPP1* polymorphisms. Mu GY \[[@pone.0135318.ref025]\] and Zhang R \[[@pone.0135318.ref028]\] observed that the high OPN expression was more frequent in samples from -443 CC carriers than TT carriers, However, Shen ZP \[[@pone.0135318.ref026]\] found that none of the polymorphisms affected the serum OPN levels, Wang JL \[[@pone.0135318.ref010]\] thought that carriers of CC and CT genotype of -443 presented lower serum osteopontin levels than those of TT genotype. Among the four studies only two gave the accurate data, so we cannot offer further statistics. The result may be caused by following reasons: (1) the *SPP1* polymorphisms affected the tumor OPN expression level, but not the serum OPN level; (2) the association is indeed related and further studies are just needed; (3) *SPP1* polymorphisms make no difference in OPN level.

Some advantage could be highlighted in this meta-analysis. On one hand, this research shed lights on the relationship of genetic polymorphisms in *SPP1* gene and the increased susceptibility to human cancers in Chinese population systematically. One the other hand, the exhaustive inclusion criteria and articles on wide range of cancers enhanced the power and persuasion of our conclusion. Furthermore, all literatures included had acceptable quality scores (scored at least 6). Meanwhile, we were also aware of several limitations of our study. First, all eligible studies come from China and the patients are Chinese population. Second, the number of the studies, especially for -66T\>G polymorphism, was not sufficiently large, Third, for -443T\>C polymorphism, the heterogeneity was big, the comprehensive analysis should be explain with caution.

Conclusions {#sec017}
===========

This meta-analysis indicated that in Chinese population the -156G\>GG polymorphism of *SPP1* may increase the susceptibility of human cancers, while -443T\>C mutation is not associated with cancer risk. For -66T\>G polymorphism, it may be a protective factor for human cancers. Accordingly, large and well-designed studies are warranted to validate our findings. The populations in this study only came from China. Thus, populations of other ethnicities should be involved in future studies.
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